CAPRICOR THERAPEUTICS, INC. — Form 8-K
Filed August 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Capricor announced the FDA extended the PDUFA target action date for Deramiocel (CAP-1002) from August 22, 2026 to November 22, 2026—a 3-month delay. The company submitted a major amendment on August 24, 2026 including 24-month open-label extension data from the Phase 3 HOPE-3 study and additional analyses, with a refined proposed indication focused on upper limb function (the primary endpoint). The FDA accepted the amendment citing significant unmet medical need in DMD.
Why this rating
3-month regulatory delay on lead asset is material for ~$400M biotech; however, FDA acceptance of amendment and focus on met primary endpoint is encouraging, offsetting negative momentum.
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.